Loading clinical trials...
Loading clinical trials...
Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in PD-L1-Negative or Immunotherapy-refractory Esophagogastric Adenocarcinoma
Conditions
Interventions
OBP-301
Pembrolizumab
Locations
2
United States
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
April 25, 2024
Primary Completion Date
April 1, 2028
Completion Date
April 1, 2030
Last Updated
April 23, 2026
NCT05969860
NCT04895709
NCT04704661
NCT06901531
NCT07462923
NCT05733689
Lead Sponsor
Weill Medical College of Cornell University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions